Phosphorylation of 5-lipoxygenase at Ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin A4 production

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 3515-3523

  Ye, Yumei ^a,b   Lin, Yu ^a   Perez Polo, Jose R ^b   Uretsky, Barry F ^a   Ye, Zaiming ^b   Tieu, Brian C ^b   Birnbaum, Yochai ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; CYCLOOXYGENASE 2; LEUKOTRIENE B4; LIPOXIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PIOGLITAZONE; PROTEIN KINASE; SERINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; HEPTANOIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; ISOQUINOLINE DERIVATIVE; LIPOXIN A; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; IMMUNOPRECIPITATION; INFLAMMATION; MALE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; IMMUNOLOGIC FACTORS; ISOQUINOLINES; LEUKOTRIENE B4; LIPOXINS; MALE; MYOCARDIUM; PHOSPHORYLATION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SERINE; SULFONAMIDES; THIAZOLIDINEDIONES;

EID: 51549090433     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.3515     Document Type: Article

References (69)

1. Agarwal, R. 2006. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am. J. Physiol. 290: F600-F605. (Pubitemid 43724959)
2. Shimizu, H., I. S. Oh, T. Tsuchiya, K. I. Ohtani, S. Okada, and M. Mori. 2006. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in type 2 diabetic patients: a randomized study. Diabet. Med. 23: 253-257.
3. Marketou, M. E., E. A. Zacharis, D. Nikitovic, E. S. Ganotakis, F. I. Parthenakis, N. Maliaraki, and P. E. Vardas. 2006. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 57: 211-218.
4. Sola, S., M. Q. Mir, S. Lerakis, N. Tandon, and B. V. Khan. 2006. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. 47: 332-337. (Pubitemid 43063250)
5. 4 by pioglitazone and atorvastatin in the rat. Circulation 114: 929-935.
6. 4 analogs block extracellular signal-regulated kinasedependent TNF-α secretion from human T cells. J. Immunol. 170: 6266-6272.
7. 4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189: 1923-1930.
8. 4, is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13: 1657-1662.
9. 4 inhibit tumor necrosis factor-α-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. J. Periodontal. Res. 34: 370-373.
10. 4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA 99: 13266-13271.
11. Chiang, N., C. N. Serhan, S. E. Dahlen, J. M. Drazen, D. W. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink. 2006. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58: 463-487. (Pubitemid 44394909)
12. Serhan, C. N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukotrienes Essent. Fatty Acids 73: 141-162.
13. Fiorucci, S., E. Distrutti, A. Mencarelli, A. Morelli, S. A. Laufor, G. Cirino, and J. L. Wallace. 2003. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br. J. Pharmacol. 139: 1351-1359. (Pubitemid 37028339)
14. Gilroy, D. W. 2005. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukotrienes Essent. Fatty Acids 73: 203-210. (Pubitemid 41253477)
15. Schwab, J. M., and C. N. Serhan. 2006. Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol. 6: 414-420.
16. El Kebir, D., L. Jozsef, T. Khreiss, W. Pan, N. A. Petasis, C. N. Serhan, and J. G. Filep. 2007. Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J. Immunol. 179: 616-622. (Pubitemid 46986579)
17. Mitchell, S., G. Thomas, K. Harvey, D. Cottell, K. Reville, G. Berlasconi, N. A. Petasis, L. Erwig, A. J. Rees, J. Savill, et al. 2002. Lipoxins, aspirintriggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13: 2497-2507.
18. Claria, J., and C. N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92: 9475-9479.
19. Fiorucci, S., L. Santucci, J. L. Wallace, M. Sardina, M. Romano, P. del Soldato, and A. Morelli. 2003. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. USA 100: 10937-10941. (Pubitemid 37140131)
20. Claria, J., and A. Planaguma. 2005. Liver: the formation and actions of aspirintriggered lipoxins. Prostaglandins Leukotrienes Essent. Fatty Acids 73: 277-282. (Pubitemid 41253487)
21. 4. Am. J. Physiol. 277: C870-C877.
22. Claria, J., M. H. Lee, and C. N. Serhan. 1996. Aspirin-triggered lipoxins (15- epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 2: 583-596. (Pubitemid 26353107)
23. 4 in the rat heart. Prostaglandins Other Lipid Mediat. 83: 89-98.
24. Radmark, O., and B. Samuelsson. 2005. Regulation of 5-lipoxygenase enzyme activity. Biochem. Biophys. Res. Commun. 338: 102-110.
25. 2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196: 147-153.
26. 2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils. Eur. J. Biochem. 238: 250-258.
27. Luo, M., S. M. Jones, N. Flamand, D. M. Aronoff, M. Peters-Golden, and T. G. Brock. 2005. Phosphorylation by protein kinase A inhibits nuclear import of 5-lipoxygenase. J. Biol. Chem. 280: 40609-40616. (Pubitemid 41780551)
28. Harris, M. B., M. A. Blackstone, S. G. Sood, C. Li, J. M. Goolsby, V. J. Venema, B. E. Kemp, and R. C. Venema. 2004. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am. J. Physiol. 287: H560-H566.
29. Shah, D. I., and M. Singh. 2006. Activation of protein kinase A improves vascular endothelial dysfunction. Endothelium 13: 267-277. (Pubitemid 44463535)
30. Manickavasagam, S., Y. M. Ye, Y. Lin, R. J. Perez-Polo, M. H. Huang, C. Y. Lui, M. G. Hughes, D. J. McAdoo, B. F. Uretsky, and Y. Birnbaum. 2007. The cardioprotective effect of a statin and cilostazol combination: relationship to akt and endothelial nitric oxide synthase activation. Cardiovasc. Drugs Ther. 21: 321-330. (Pubitemid 47598922)
31. Birnbaum, Y., Y. Ye, S. Rosanio, S. Tavackoli, Z. Y. Hu, E. R. Schwarz, and B. F. Uretsky. 2005. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc. Res. 65: 345-355. (Pubitemid 40082476)
32. Atar, S., Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, S. Rosanio, M. H. Huang, B. F. Uretsky, J. R. Perez-Polo, and Y. Birnbaum. 2006. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am. J. Physiol. 290: H1960-H1968.
33. Ye, Y., Y. Lin, S. Atar, M. H. Huang, J. R. Perez-Polo, B. F. Uretsky, and Y. Birnbaum. 2006. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am. J. Physiol. 291: H1158-H1169. (Pubitemid 44343659)
34. Kim, S. F., D. A. Huri, and S. H. Snyder. 2005. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310: 1966-1970. (Pubitemid 43005992)
35. Patel, H. H., B. P. Head, H. N. Petersen, I. R. Niesman, D. Huang, G. J. Gross, P. A. Insel, and D. M. Roth. 2006. Protection of adult rat cardiac myocytes from ischemic cell death: role of caveolar microdomains and -opioid receptors. Am. J. Physiol. 291: H344-H350.
36. 4 ELISA. J. Pharmacol. Exp. Ther. 287: 779-790.
37. Huang, M. H., J. J. Bahl, Y. Wu, F. Hu, D. F. Larson, W. R. Roeske, and G. A. Ewy. 2005. Neuroendocrine properties of intrinsic cardiac adrenergic cells in fetal rat heart. Am. J. Physiol. 288: H497-H503.
38. 4 in chemotactic peptide-stimulated human neutrophils. FASEB J. 12: 1521-1531.
39. Radmark, O., O. Werz, D. Steinhilber, and B. Samuelsson. 2007. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32: 332-341. (Pubitemid 47021417)
40. Peters-Golden, M., and W. R. Henderson, Jr. 2007. Leukotrienes. N. Engl. J. Med. 357: 1841-1854.
41. Linde, A., D. Mosier, F. Blecha, and T. Melgarejo. 2007. Innate immunity and inflammation: new frontiers in comparative cardiovascular pathology. Cardiovasc. Res. 73: 26-36. (Pubitemid 44937178)
42. Wilson, E. M., A. Diwan, F. G. Spinale, and D. L. Mann. 2004. Duality of innate stress responses in cardiac injury, repair, and remodeling. J. Mol. Cell. Cardiol. 37: 801-811.
43. Fredj, S., J. Bescond, C. Louault, and D. Potreau. 2005. Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J. Cell. Physiol. 202: 891-899. (Pubitemid 40175867)
44. Woods, J. W., J. F. Evans, D. Ethier, S. Scott, P. J. Vickers, L. Hearn, J. A. Heibein, S. Charleson, and I. I. Singer. 1993. 5-Lipoxygenase and 5-lipoxygenase- activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 178: 1935-1946.
45. 4-synthesizing function of macrophage lipid bodies elicited by innate immune response. J. Immunol. 179: 8500-8508.
46. Maya-Monteiro, C. M., P. E. Almeida, H. D'Avila, A. S. Martins, A. P. Rezende, H. Castro-Faria-Neto, and P. T. Bozza. 2008. Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent mechanism. J. Biol. Chem. 283: 2203-2210.
47. Glover, S., M. S. de Carvalho, T. Bayburt, M. Jonas, E. Chi, C. C. Leslie, and M. H. Gelb. 1995. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J. Biol. Chem. 270: 15359-15367.
48. Parfenova, H., V. N. Parfenov, B. V. Shlopov, V. Levine, S. Falkos, M. Pourcyrous, and C. W. Leffler. 2001. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am. J. Physiol. 281: C166-C178. (Pubitemid 32927327)
49. Parfenova, H., T. H. Eidson, and C. W. Leffler. 1997. Up-regulation of COX-2 in cerebral microvascular endothelial cells by smooth muscle cell signals. Am. J. Physiol. 273: C277-C288. (Pubitemid 27343975)
50. Steinhilber, D. 1994. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. 69: 3-14. (Pubitemid 24246734)
51. Rouzer, C. A., A. W. Ford-Hutchinson, H. E. Morton, and J. W. Gillard. 1990. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem. 265: 1436-1442. (Pubitemid 20048962)
52. Dwyer, J. H., H. Allayee, K. M. Dwyer, J. Fan, H. Wu, R. Mar, A. J. Lusis, and M. Mehrabian. 2004. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350: 29-37.
53. Hakonarson, H., S. Thorvaldsson, A. Helgadottir, D. Gudbjartsson, F. Zink, M. Andresdottir, A. Manolescu, D. O. Arnar, K. Andersen, A. Sigurdsson, et al. 2005. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. J. Am. Med. Assoc. 293: 2245-2256. (Pubitemid 40629191)
54. Helgadottir, A., A. Manolescu, G. Thorleifsson, S. Gretarsdottir, H. Jonsdottir, U. Thorsteinsdottir, N. J. Samani, G. Gudmundsson, S. F. Grant, G. Thorgeirsson, et al. 2004. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36: 233-239. (Pubitemid 38282747)
55. Lohmussaar, E., A. Gschwendtner, J. C. Mueller, T. Org, E. Wichmann, G. Hamann, T. Meitinger, and M. Dichgans. 2005. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36: 731-736. (Pubitemid 40490615)
56. Helgadottir, A., S. Gretarsdottir, D. St. Clair, A. Manolescu, J. Cheung, G. Thorleifsson, A. Pasdar, S. F. Grant, L. J. Whalley, H. Hakonarson, et al. 2005. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76: 505-509. (Pubitemid 40250529)
57. Topol, E. J., J. Smith, E. F. Plow, and Q. K. Wang. 2006. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum. Mol. Genet. 15: R117-R123. (Pubitemid 44446784)
58. Kajimoto, K., K. Shioji, C. Ishida, Y. Iwanaga, Y. Kokubo, H. Tomoike, S. Miyazaki, H. Nonogi, Y. Goto, and N. Iwai. 2005. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ. J. 69: 1029-1034. (Pubitemid 41603086)
59. Helgadottir, A., A. Manolescu, A. Helgason, G. Thorleifsson, U. Thorsteinsdottir, D. F. Gudbjartsson, S. Gretarsdottir, K. P. Magnusson, G. Gudmundsson, A. Hicks, et al. 2006. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38: 68-74. (Pubitemid 43011884)
60. Flamand, N., J. Lefebvre, M. E. Surette, S. Picard, and P. Borgeat. 2006. Arachidonic acid regulates the translocation of 5-lipoxygenase to the nuclear membranes in human neutrophils. J. Biol. Chem. 281: 129-136. (Pubitemid 43671171)
61. Goodman, J. E., E. D. Bowman, S. J. Chanock, A. J. Alberg, and C. C. Harris. 2004. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 25: 2467-2472.
62. Manev, H., and R. Manev. 2006. 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med. Hypotheses 66: 501-503. (Pubitemid 43060163)
63. Qu, T., R. Manev, and H. Manev. 2001. 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 13: 304-305. (Pubitemid 32499684)
64. Manev, H. 2000. 5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease. Med. Hypotheses 54: 75-76. (Pubitemid 30156639)
65. Drazen, J. M., C. N. Yandava, L. Dube, N. Szczerback, R. Hippensteel, A. Pillari, E. Israel, N. Schork, E. S. Silverman, D. A. Katz, and J. Drajesk. 1999. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22: 168-170.
66. Poynter, J. N., S. B. Gruber, P. D. Higgins, R. Almog, J. D. Bonner, H. S. Rennert, M. Low, J. K. Greenson, and G. Rennert. 2005. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352: 2184-2192.
67. Sparks, D. L., M. Sabbagh, D. Connor, H. Soares, J. Lopez, G. Stankovic, S. Johnson-Traver, C. Ziolkowski, and P. Browne. 2006. Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185: 78-86.
68. L expression levels and their subcellular distributions. J. Neurotrauma 22: 1164.
69. A results in apoptosis resistance. Cancer Sci. 95: 266-270.